Evolution of Viral Load in Patients Infected with HIV-1 at Point G University Hospital

Introduction: HIV, the human immunodeficiency virus, is the etiological agent of acquired immunodeficiency syndrome (AIDS). The aim of this study was to assess the evolution of the viral load in patients under treatment. Methodology: This was a study carried out from July 2017 to June 2022 at the Point G University Hospital laboratory. The determination of the viral load of patients was carried out by PCR on the ABOTT M2000sp/rt platform. Results: A total of 129 patients infected with HIV-1, aged 19 to 72 years with a mean age of 40.05 years ± 10.71;all on antiretroviral chemotherapy. The female gender predominated among our patients. The most common treatment regimen was 2INTI + 1INNTI with 72.9% followed by 2INTI + 1INI with 13.2%. As for the combinations of molecules, the combination TDF + 3TC + EFV and TDF + 3TC + DTG predominated, respectively 65.1% and 13.2%. 89.9% of our patients had undetectable viremia after 12 months of treatment (p < 0.005) with an average viral load which had evolved from 681315.65 copies/ml ± 1616908.484 to M0 at 5742.36 copies /ml ± 35756.883 at M12 (p Conclusion: Generally speaking, antiretroviral treatment had contributed to controlling viral loads, however the therapeutic combination TDF + 3TC + DTG had made it possible to obtain more patients with undetectable viremia instead.

Xpert HIV-1病毒载量检测试剂盒的检测线性和精密度评估

目的 评价1型艾滋病病毒(HIV-1),Xpert病毒载量测定试剂盒的检测线性、精密度及与参比试剂的符合性。方法 采用定值质控物对Xpert病毒载量进行测定,并对其进行线性及精密度测定。采集血样383份,采用双盲试验法,以TaqMan病毒载量测定试剂进行检验。依据多项卫生推荐标准(WS/T),利用卡方检验和Kappa检验法对两种试剂进行定性检验;采用多元回归、Bland-Altman模型等统计学方法对两种试剂进行一致性比较。结果 用Xpert病毒载量测定试剂对给定的质控物有很好的线性关系,批内和批间的方差都在10%以内。用1 000个copies/mL和5 000个copies/mL作为检测线,两种方法的一致性分别为97.91%、97.12%。卡方检定和Kappa分别为P=0.549(>0.05)和0.919(P<0.001),表明两者的诊断具有良好的一致性。两种方法的测定值之间的相关性为0.890,相关系数R^(2)=0.896。通过Bland-Altman模型比较,发现两种试剂的检出值均在95%上下限范围内的符合率为98.79%(327/331)。在1 000 copies/mL以下,病毒载量的相关性相对较低。结论 评价试剂(Xpert)与参比试剂(TaqMan)在整体上具有很好的一致性,可以满足大部分的临床检验需要。

Interventions to Improve HIV Viral Load Suppression among the Adolescents: Evidence of Improvement Science through a Quality Improvement Approach in Eastern Uganda

Introduction: Achieving viral load suppression among the adolescents living with HIV continues to hold back attainment of sustainable development goals. TASO Mbale realized a viral load suppression rate of 63.1% among the adolescents living with HIV in care in quarter 4 of 2016. We therefore, instituted a quality imrpovement project to improve Viral load suppression from 63.1% in quarter 4 2016 to 90% by the end of quarter 4 2017. Method: Baseline data from the Uganda viral load dashboard were analyzed, and fishbone diagram was utilized to provide root causes of low viral load suppression among the adolescents living with HIV at TASO Mbale. The identified barriers were Knowlegde gap, among the adolescents, on positive living, Missing clinic appointments, Sub-optimal adherence, Poorly planned adolescent HIV clinic, Inadequate follow-up and Low use of data for informed decisions. A plan-do-study-act (PDSA) model was applied to implement tested changes. Strategies that worked included introduction of appointment register to track appointment behaviour of the adolescents, generating lists of clients on appointment who were due for Viral Load bleeding, telephone calls for follow up, increasing the frequency of reviewing adolescents from once a month to twice a week, committing a dedicated team responsible for adolescent care. Results: The viral load suppression improved from 63.1% in quarter 4 of 2016 to 63.8% in the first quarter of 2017, to 87.5% in quarter 2 of 2017, 97.6% in the third quarter and 91.4% in quarter 4 of 2017. Conclusion: The use of quality improvement in addressing gaps in HIV service delivery is highly effective.

Evaluation of HIV Viral Load Activity at the Bacteriology-Virology Laboratory in the University Hospital Center of Brazzaville

Introduction: The bacteriology-virology laboratory of the teaching university hospital of Brazzaville, was equipped with a real-time PCR device like Miniopticon (Biorad? , France). The aim of this work was to do an evaluation of the HIV viral load activity, with a view to proposing some recommendations. Material and methods: Retrospective study, January 2013 to March 2015, in patients on first line ARV three-therapy, pre-inclusion therapy checkup in HIV positive patients, but again screening after sexual abuse in women or accident of exposure (AES). A blood sample on EDTA tube was made and RNA extraction with Qiagen kit. Ultrasensitive HIV-RNA quantification was performed using the Generic HIV real-time PCR assay (Biocentric?, Bandol, France). Results: 126 patients were included. The mean age was 37.63 years +/- 10.43 years, sex ratio F/H = 2.3. The HIV viral load was detectable in 94 cases (74.6%). Concerning patients with detectable viral load (copies/ml): 403 to 996 in 35 cases (37.23%), 1411 to 1812 in 41 cases (43.62%) and >1814 in 5 cases (5.32%) (therapeutic failure). Conclusion: This work reports success in the setting up of the molecular biology unit. Procedures that implement information and education actions on the risks associated with AES must be disclosed.

Stroke and HIV: Correlation between Viral Load and Type of Stroke

Introduction: The role of immunosuppression of TCD4+ lymphocytes in the onset of stroke in people living with HIV has been reported in numerous studies examining the co-morbidity of stroke and HIV. Objective: To determine the correlation between the viral load and the type of stroke. Methodology: This was a 7-month cross-sectional descriptive study carried out in the Neurology Department of Loandjili General Hospital in Pointe-Noire. The study population consisted of patients living with HIV who had a stroke confirmed by brain scan. The sero-immunological investigation consisted of looking for T lymphocyte typing from two kits: a CD4+ T lymphocyte typing reagent kit (BD FACS Presto TM) and a GeneXpert kit for viral load (Xpert®HIV-1 Viral Load). The database was made from the 2010 version of Microsoft Excel. Results: We included 16 patients living with HIV, 56% of whom were women with a sex ration of 0.78. The mean age was 56.92 ± 11.21. The mean number of TCD4+ lymphocytes was 413.44 ± 677.95/mm3;minimum: 93/mm3;maximum: 2854/mm3. The mean viral load was 17,996.31 ± 20,982.22/mm3;minimum: 1002/mm3;maximum: 67,229/mm3. No significant difference between the viral load and the occurrence of the stroke (p = 0.13). Conclusion: Our study did not show a causal link between viral load, immunosuppression of TCD4+ lymphocytes and the onset of stroke.

HIV-1 Viral Load and CD4 Assessment in HIV-1 Infected Pregnant Women Supported as Part of PMTCT in N’Djamena, Chad

In Sub-Saharan Africa, HIV affects lots of women of childbearing age;without prevention they can transmit the virus to their child. A cross-sectional study was conducted in the center of Psycho Medico-Social Support (APMS) in N’Djamena, Chad from January 2014 to March 2015. Our sampling concerned HIV-1 infected pregnant women followed up for PMTCT and their newborn. CD4+ lymphocytes and HIV-1 viral load were tested respectively with PIMATM and Abbott m2000 Real Time in mothers. Early infant diagnosis of HIV-1 was done in Children using PCR tool (Abbott m2000 Real Time). Pregnant women included in the study had a median age of 25 years (IQR, 22 - 30 years). Most of them (75.6%) (34/45), were under combination ART (TDF + 3TC or FTC + EFV). The median duration on ART was 4 month (IQR [3 - 5 months]). Nevirapine syrup was administrated to newborns as prophylaxis at least for the first six weeks of life until EID was done. At ART initiation, mothers’ LTCD4+ median was 249 cells/mm3 (IQR: 95 - 674 cells/mm3). After a median duration of 4 months on ART, LTCD4+ median was 530 cells/mm3 (IQR [263 - 1220 cells/mm3]). Viral load assessment in mothers showed that 15.5% (7/45) were undetectable, 75.6% (34/45) were detectable with a VL < 3log copies/ml and 8.8% (4/45) at virologic failure (VL > 3log copies/ ml). Four (11.4%) of 35 children included were tested positive at EID for HIV-1. Antiretroviral treatment management in pregnant women can improve their health and reduce the risk of MTCT. Availability of virologic monitoring in routine is essential for pregnant women in resources limited setting for preventing HIV transmission to their new-born and keep them alive.

Role of HIV-1 Viral Load in Initiating Antiretroviral Therapy

Purpose: For commencement of Antiretroviral Therapy (ART), CD4 count and/or WHO clinical staging is used as the guide in India. In western countries along with clinical and immunological criteria, HIV-1 viral load is also used to start the patient on treatment. The present study was conducted to determine the role of viral load in taking decision on ART commencement in HIV-1 infected treatment na?ve individuals. Method: A cross sectional study was carried out at the Integrated Counseling and Testing Centre (ICTC) in the Department of Microbiology at a Tertiary care teaching hospital after Institutional Ethics Committee approval. After obtaining written informed consent, HIV-1 infected patients who were clinically asymptomatic, ART na?ve, having CD4 count ? TaqMan? HIV-1 Test. Result: During the study period of one year, 8966 HIV-1 infected patients were referred for CD4 count estimation. Of these 1624 patients had CD4 count <250 cells/mm3 and 405 patients were treatment na?ve. Of these 96 (23.70%) patients were clinically asymptomatic and were enrolled. Of those enrolled, ten (10.41%) had viral load less than 5000 copies/ml. Conclusion: Decision to start patient on ART can be made judiciously when viral load is used along with CD4 count estimation.

凉山地区HIV/AIDS患者皮肤黏膜病变及流行病学特征分析

目的分析凉山地区HIV/AIDS患者皮肤黏膜病变及流行病学特征,以期为当地艾滋病防控工作提供参考。方法回顾性分析凉山地区某二级甲等综合医院2022年6月—2023年5月就诊的HIV/AIDS合并皮肤黏膜病变患者。检测其HIV病毒载量和CD4^(+)T淋巴细胞计数,收集性别、年龄以及HIV感染途径等一般资料。结果根据纳入标准,共纳入78例研究对象,男性48例(61.54%),女性30例(38.46%),中位年龄31岁(1~68岁)。婚姻状况中,以已婚为主(56例,71.80%)。艾滋病传播途径中,以异性性行为为主(58例,74.36%)。HIV病毒载量与CD4^(+)T淋巴细胞计数两者呈负相关(r=-0.328,P=0.012)。78例研究对象中,感染性皮肤黏膜病变32例(41.03%),以口腔念珠菌病和梅毒为主;非感染性皮肤黏膜病变46例(58.97%),以湿疹和脂溢性皮炎为主。随着CD4^(+)T淋巴细胞计数水平升高,皮肤黏膜病变发生率逐渐降低。当CD4^(+)T淋巴细胞计数<100 cells/μL时,皮肤黏膜病变发生率高,并常合并2种及以上皮肤黏膜病变。结论凉山地区HIV/AIDS患者皮肤黏膜病变表现复杂,合并疾病种类较多。因此,针对HIV/AIDS患者需进行详细的检查和诊断,及早发现罹患的皮肤黏膜病变。

试剂加样间隔时间对HIV抗体ELISA结果的影响分析

目的研究不同试剂加样间隔时间对HIV抗体酶联免疫检测结果准确性的影响。方法以单因素试验分析不同试剂加样间隔时间对检测结果的影响,再根据单因素试验结果进行正交试验。结果加酶、显色剂间隔时间越长,PC和QC的检测结果越低。加酶间隔时间从45 min开始,PC出现失控的情况;加显色剂间隔时间从45 min开始,QC出现告警和失控的情况。正交试验结果显示加酶和显色剂的时间要控制在15 min以内。结论加酶、显色剂间隔时间过长对检测结果影响较大,加酶、显色剂的间隔时间要控制在15 min以内。

Enhanced Adherence Counselling, Support Groups and Viral Load Suppression amongst HIV-Positive Adolescents in a Tertiary Health Care Facility in Cameroon

Background: Globally, HIV viral load suppression rate, which is an indirect measure of the efficacy of antiretroviral (ART) medication, is 47% and 52% in Africa. In Cameroon, the viral load (VL) suppression rate is 44.7% and poor adherence is widely documented as being responsible for the large gap in VL Suppression. Enhanced adherence counselling (EAC) sessions, and enrolment and participation in support groups are specific interventions to improve ART adherence and improve viral load suppression. Purpose: This study assesses the uptake and contribution of support groups and EAC sessions in the management of adolescents with unsuppressed VL results at Centre Hospitalier d’Essos, Yaounde. Methods: A retrospective correlational quantitative patient files review was conducted for 138 files of HIV positive adolescents aged between 10 - 19 years with HIV VL above 1000 copies/ml enrolled in care between January 2009 and December 2019. Data from the questionnaire was entered into CSPRO version 7.4. and analyzed by using SPSS version 25.0. Results: A total of 138 participants (75 females and 63 males) with a mean age of 15 ± 3 years were included in our study. Sixty-nine (50%) participants were in World Health Organization (WHO) stage I;32.6% were in Stage II;13.0% and 4.3% were in stages III and IV, respectively. Thirty (21.7%) had a history of tuberculosis and 76% of the adolescents were being cared for primarily by their parents. The charts of the adolescents revealed that there was an association between completion of EAC sessions in adolescents with unsuppressed VL and eventual VL suppression (R.R = 2.5;CI 0.848 - 6.162;p = 0.033). However, there was no significant association between support group enrolment and active participation, and eventual VL Suppression. Furthermore, combining EAC and support group interventions was strongly associated with eventual VL Suppression in this group of initially unsuppressed adolescents (R.R = 7.5;C.I 2.544 - 22.360;p Conclusion: Suppression rates were good after completion of EAC sessions and participation in support group enrolment for adolescents with a high VL. As we move towards having 95% of ART-treated adolescents achieve and maintain viral suppression, there is a need to reinforce EAC sessions and support group enrolment in ART clinics targeting this priority group.

HIV低病毒载量患者耐药检测的可行性及临床预后研究

目的评价人类免疫缺陷病毒(HIV)低病毒载量患者全血样本HIV前病毒DNA基因型耐药性检测(DNA GRT)与血浆HIV-RNA基因型耐药性检测(RNA GRT)的可行性,并分析HIV低病毒载量患者的临床预后。方法收集2018年1月至2021年12月云南省传染病医院低病毒载量(HIV RNA在200~1000 copy/mL)样本212份,进行RNA GRT。同时抽取40份样本分别进行DNA GRT。比较2种方法的扩增效果,以及2种方法检测40例样本的耐药结果;分析低病毒载量样本的耐药情况及低病毒载量对临床治疗效果的影响。结果进行RNA GRT的212份样本中扩增成功107份,扩增率为59.22%;进行DNA GRT的40份样本扩增成功24例,扩增率为60.0%。2种方法联合检测总扩增率为90%(36/40)。40份样本中采用两种方法共同获得耐药检测结果的有21份,其中2种方法检测结果完全一致的样本有10份(47.62%),蛋白酶类耐药突变位点不一致的样本有2份(9.52%),核苷类和非核苷类耐药突变位点不一致的样本有9份(42.86%)。107份RNA GRT扩增成功的样本中,持续性低病毒载量的耐药率为48.28%(14/29),一过性低病毒载量的耐药率为41.38%(12/29),基线低病毒载量的耐药率为6.25%(1/16)。29份持续性低病毒载量样本中,在后期12个月随访中有14例(48.28%)病毒载量<50 copy/mL,有2例(6.90%)病毒载量>1000 copy/mL。16例基线低病毒载量样本中,在后期12个月随访中有1例(6.25%)出现病毒载量>1000 copy/mL,其余病毒载量均<50 copy/mL。结论HIV低病毒载量患者进行耐药检测是可行的,应尽早识别耐药突变位点更换治疗方案,预防后期治疗失败。

Factors Associated with HIV/Tuberculosis Coinfection among People Living with HIV after Initiation of Antiretroviral Treatment in Lingwala Health Zone from 2021 to 2023

Context and objective: Around 8% of incident cases of tuberculosis (TB) were reported among people living with HIV worldwide in 2022. Tuberculosis is the leading cause of death among people living with HIV. Africa accounts for the majority of co-infection episodes, with over 50% of cases in some parts of southern Africa. In the Democratic Republic of Congo (DRC), around 9% of persons living with HIV (PLHIV) develop TB and 11% of TB patients are infected with HIV. The DRC is one of the 30 countries in the world bearing the brunt of co-infection. Despite the efforts made by countries to improve access to antiretroviral traitement (ART), TB remains a major problem among people living with HIV. The Lingwala Health Zone in the provincial city of Kinshasa recorded a large number of cases of HIV/TB co-infection during the study period. The aim of this study was to determine the factors associated with HIV/TB co-infection among PLHIV on ART in the Lingwala health zone (HZ) in Kinshasa. Methods: This was a case-control study conducted in the state-run HIV care facilities in the Lingwala health district among PLHIV who had visited the health facilities during the period 2021-2023. Cases were coinfected patients and controls were PLHIV who had not developed tuberculosis during the study period. Results: A total of 281 PLHIV were enrolled in the study, with 70 cases and 211 controls. Factors associated with HIV/TB co-infection after multivariate analysis were viral load (OR = 5.34;95% CI;1.8-15.8, p = 0.005). History of tuberculosis (OR = 20.84;95% CI;8.6-50.3, p -85.0, p = 0.005) and BMI Conclusion: The results of this study indicate that the detection of these enumerated factors should prompt providers to actively search for tuberculosis with a view to organising early management.

HIV病毒感染细胞的体内分布及关键抑制因素

目的 研究HIV感染细胞的体内分布及关键抑制因素,了解HIV在体内的生物学特性,了解艾滋病毒在患者体内的分布,并对抑制因素的分析发现新的治疗靶点和药物,为艾滋病的预防和治疗提供科学依据。方法 采用横断面回顾分析,选取2020年4月至2022年4月贵州某医院感染科接受治疗的艾滋病患者252例为研究对象。按照疾病分期将患者病例分为感染期和艾滋病期,记录两组患者的一般资料,根据两组患者艾滋病毒体内分布、关键抑制因素及不同分期感染病毒载量的分析来判断艾滋病病毒对不同分期患者产生的影响。结果 两组患者的性别、年龄、吸烟史、高血压、糖尿病史、饮酒史等指标比较均无差异(P>0.05);两组患者唾液、汗液和尿液比较均无差异(P>0.05);两组患者未检出率以及各病毒载量的区间差异均有统计学意义(P<0.05);两组患者血液、精液/阴道分泌物、关节液、腹腔积液中的病毒载量对比差异均有统计学意义(P<0.05);两组患者体内GP160、GP120、GP41及P24的产生情况比较均无差异(P>0.05);P66、P55、P51、P31、P17的产生情况差异均有统计学意义(P<0.05)。结论 艾滋病患者血液、精液/阴道分泌物、关节液、腹腔积液中的病毒载量较多,且艾滋病期患者体内的病毒载量要明显高于感染期;艾滋病患者体内P66、P55、P51、P31、P17特异性抗体与感染期患者均有统计学差异,提示可作为艾滋病分期的参考指标。

2004—2022年河南省平顶山市HIV/AIDS患者抗病毒治疗效果分析

目的通过分析平顶山市2004—2022年人类免疫缺陷病毒(HIV)/艾滋病(AIDS)患者抗病毒治疗情况,评估抗病毒治疗效果,为本区域的艾滋病防治工作提供科学依据。方法使用“中国疾病预防控制信息系统”,下载2004—2022年现地址在平顶山市,抗病毒治疗满6个月及以上的HIV/AIDS病例数据资料,检测CD4^(+)T淋巴细胞和病毒载量,分别作为抗病毒治疗效果的免疫学和病毒学评价指标。对数据统计分析采用SPSS 22.0。结果共纳入2186例患者,治疗前基线CD4^(+)T细胞计数均值为(286.32±189.81)个/μl,抗病毒治疗后最近一次随访检测CD4^(+)T细胞计数均值为(446.45±221.96)个/μl,抗病毒治疗前后CD4^(+)T细胞结果分布差异有统计学意义(χ^(2)=641.53,P<0.001)。患者最近一次随访检测VL<20 copies/ml有1875例(85.77%),构成比呈逐渐上升趋势(χ^(2)=16.970,P<0.001)。Spearman检验抗病毒治疗后CD4^(+)T细胞与VL结果呈负相关(r=-0.143,P<0.001)。结论平顶山市在治的抗病毒治疗HIV/AIDS患者,免疫重建和病毒抑制情况较好,应继续扩大检测、早发现、早治疗,加强患者服药依从性教育,坚持长期规范治疗,进一步提高抗病毒治疗质量。

中药复方普乐康治疗HIV/AIDS的临床研究

目的:观测中药复方普乐康口服液治疗HIV/AIDS的临床疗效。方法:使用普乐康口服液临床治疗不同疾病期的AIDS患者共12例,观察服药前后患者AIDS机会性感染及其多种并发症的疗效,并测定治疗前后患者外周血中的CD4+、CD8-T淋巴细胞计数及HIV-RNA变化值。结果:患者12例(早期4例,中期5例,晚期2例,临终期1例)服用普乐康口服液3个月后能全面改善AIDS临床症状,完全缓解率平均为44.7%,显效率28.0%,总有效率91.6%。服药3 个月、6个月后,CD4+平均增加值分别为173.92.179.58 cells/μl;HIV载量平均下降值为65.27 cp/ml,129.16 cp/ml,其中有两例HIV载量检测不出(早期、中期各1例),并未发现明显毒副作用。结论:普乐康口服液治疗不同年龄不同疾病期HIV/AIDS感染者,能明显降低机会性感染及其并发症,能使免疫功能恢复正常,HIV载量明显下降。

北京市MSM人群HIV感染者合并HCV与梅毒感染的状况及相应免疫指标与病毒载量的变化

目的 了解北京市男男性接触者（MSM）的艾滋病病毒（HIV）感染及宿主的免疫状态。方法 2005年7～12月对招募的MSM进行HIV感染检测，采集阳性感染者的外周血，对分离毒株进行鉴定，并对阳性感染者的免疫状态包括CD4^＋、CD8^＋T细胞的数量，以及感染者体内病毒载量进行了分析。结果在招募的526名MSM中，HIV感染的主要流行亚型为欧美B亚型，1例为CRF01-AE重组亚型，后者主要为异性间HIV感染的流行亚型。HIV感染者中合并HCV或者梅毒的感染率分别为17．65％与35．29％，合并感染者的CD4^＋、CD8^＋T淋巴细胞数量明显降低，病毒载量明显升高。结论 MSM人群中HIV感染者合并STD感染，明显降低宿主免疫系统控制病毒复制的能力，同时存在着MSM人群与其他高危人之间通过性途径相互传播HIV的趋势。

HIV病毒载量定量测定方法的比较研究

[目的 ] 比较不同检测方法对人类免疫缺陷病毒 (HIV )病毒载量间的一致性 ,供临床应用选择方法时参考。[方法 ] 在上海地区对HIV感染者和艾滋病 (AIDS)病人采集 91份标本 ,每份标本同时用bDNA法和NASBA法测定 ,比较两者检出率、相关性和不一致性。 [结果 ] HIV病毒载量检出率均在 80 % ,且无样本错位 ;两种方法检测的HIV病毒载量Log值呈高度线性相关 ,同时发现 7例病人两种方法测得的病毒载量存在明显差异。 [结论 ] bDNA法和NASBA法检测HIV病毒载量具有高度一致性 ,在实际工作中可任意选用 ,NASBA法在HIVRNA低浓度时敏感性更高 。

不同核酸提取方法检测HIV病毒载量和耐药基因的研究

目的比较5种核酸提取法提取HIV RNA的效率。方法收集2015年HIV病毒感染者血样,使用不同核酸提取方法平行检测Ct值及载量值,分析检测的检出率、敏感性、变异系数、稳定性,并进行耐药扩增。结果 5种提核酸方法检出率国产磁珠法最高,5种方法差异无统计学意义(χ2=7.98,P=0.09);Ct值从小到大顺序为:国产磁珠法≥离心柱法>大批量法≥进口磁珠法>试剂盒自带法;重复性比较表明国产磁珠法检测结果较稳定;核酸胶显示国产磁珠法提取RNA浓度最高;提取方法不影响耐药关键位点检测。结论 5种核酸提取方法均能检测HIV信息,国产磁珠法提取病毒核酸进行检测,敏感性和稳定性均较高。

中药(XQ-9302)治疗HIV感染者/AIDS患者CD_4细胞计数和病毒载量变化的评价

目的 探讨中药 (XQ 930 2 )对艾滋病病毒 (HIV)感染者 /艾滋病 (AIDS)患者的治疗作用。方法 测定XQ 930 2治疗 2 1例HIV感染者 /AIDS患者的CD4细胞计数和病毒载量 ,并与仅进行对症治疗的HIV感染者 /AIDS患者对照组比较。结果 经XQ 930 2治疗后 ,4 2 9%HIV感染者 /AIDS患者的CD4细胞计数上升 >5 1% ,为显效 ;33 3%患者的CD4细胞计数升高 11%～ 5 0 % ,为有效 ,总有效率为 76 2 % ;CD4细胞计数上升 <10 %为无效 ,无效率为 2 3 8%。 5 2 4 %HIV感染者 /AIDS患者的病毒载量下降≥ 1log ,呈显效 ;38 1%的HIV感染者 /AIDS患者病毒载量无变化或下降 <1log ,为有效 ;仅 9 5 %HIV感染者 /AIDS患者病毒载量上升 ,为无效。所有HIV感染者 /AIDS患者的临床症状均获改善。对照组HIV感染者 /AIDS患者病毒载量呈稳定及上升状态 ,临床症状均未获改善 ,呈无效。结论 XQ 930 2对HIV感染者 /AIDS患者的CD4细胞计数上升以及病毒载量下降有效 ,且能改善临床症状。

健脾益气方对HIV/AIDS患者病毒载量与IL-2、IL-13、IFN-γ变化影响及相关性分析

目的:探讨健脾益气方治疗HIV/AIDS患者的作用机制。方法:采用Real-time PCR与流式荧光法检测病毒载量(VL)与IL-2、IL-13、IFN-γ变化情况,分析不同VL水平细胞因子含量差异及其相关性。结果:治疗后细胞因子水平相比治疗前均有所升高;VL分组为Ⅰ组VL=0,Ⅱ组:VL=20copies/ml,Ⅲ组:20<VL<1000 copies/ml,Ⅳ组:VL>1000 copies/ml。IL-13在治疗前后差异有统计学意义,并随着VL的增加IL-13水平增高;VL与IL-13的相关性分析显示,在治疗前后均呈现中度正相关关系。结论:健脾益气方可影响HIV/AIDS患者IL-2、IL-13和IFN-γ水平,但对VL影响较小;随着病毒载量增加,血浆IL-13水平变化趋势与之相同。